Palynziq
Procedural steps taken and scientific information after the authorisation
Application 
Scope
number
Opinion/ 
Commission 
Product 
Summary
Notification1 
Decision 
Information 
issued on
Issued2 / 
affected3 
amended 
on
PSUSA/10761
Periodic Safety Update EU Single assessment - 
26/01/2023
24/03/2023
SmPC and PL
Refer to Scientific conclusions and grounds recommending 
/202205
pegvaliase
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10761/202205.
IA/0033
B.II.f.1.e - Stability of FP - Change to an approved 
16/02/2023
n/a
stability protocol
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures.
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us 
Send us a question  Go to www.ema.europa.eu/contact  Telephone +31 (0)88 781 6000
An agency of the European Union
 
IB/0032
B.I.b.2.e - Change in test procedure for AS or 
04/01/2023
n/a
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate
IB/0030
B.I.a.1.f - Change in the manufacturer of AS or of a 
09/12/2022
n/a
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place
IB/0031
B.I.a.1.f - Change in the manufacturer of AS or of a 
08/11/2022
n/a
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place
IB/0028/G
This was an application for a group of variations.
07/06/2022
24/03/2023
SmPC
B.II.g.5.c - Implementation of changes foreseen in 
an approved change management protocol - For a 
biological/immunological medicinal product
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site
B.II.e.1.z - Change in immediate packaging of the 
finished product - Other variation
IB/0027
C.I.11.z - Introduction of, or change(s) to, the 
30/05/2022
n/a
Page 2/9
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation
IB/0025
B.I.z - Quality change - Active substance - Other 
19/04/2022
n/a
variation
PSUSA/10761
Periodic Safety Update EU Single assessment - 
27/01/2022
24/03/2022
SmPC and PL
Refer to Scientific conclusions and grounds recommending 
/202105
pegvaliase
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10761/202105.
IB/0026
B.I.b.1.b - Change in the specification parameters 
21/02/2022
n/a
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits
IB/0023
B.I.a.4.z - Change to in-process tests or limits 
02/12/2021
n/a
applied during the manufacture of the AS - Other 
variation
II/0024
B.II.g.2 - Introduction of a post approval change 
25/11/2021
n/a
management protocol related to the finished product
II/0019
B.I.e.1.a - Introduction of a new design space or 
02/09/2021
n/a
extension of an approved design space for the AS - 
One unit operation in the manufacturing process of 
the AS including the resulting IPCs and/or test 
procedures
PSUSA/10761
Periodic Safety Update EU Single assessment - 
24/06/2021
18/08/2021
SmPC and PL
Refer to Scientific conclusions and grounds recommending 
/202011
pegvaliase
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10761/202011.
Page 3/9
IB/0020/G
This was an application for a group of variations.
05/08/2021
n/a
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure
B.I.b.2.c - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure for a reagent, which 
does not have a significant effect on the overall 
quality of the AS
IB/0021
B.I.e.5.c - Implementation of changes foreseen in an 
02/08/2021
n/a
approved change management protocol - For a 
biological/immunological medicinal product
II/0017
B.I.a.1.e (Type II): to introduce an additional site 
15/04/2021
n/a
responsible for the preparation, testing and storage 
of the WCB.
B.I.a.1.e - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
change relates to a biological AS or a starting 
material [-] used in the manufacture of a 
biological/immunological product
PSUSA/10761
Periodic Safety Update EU Single assessment - 
28/01/2021
26/03/2021
SmPC
Refer to Scientific conclusions and grounds recommending 
/202005
pegvaliase
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10761/202005.
Page 4/9
II/0014
B.I.e.2 - Introduction of a post approval change 
04/02/2021
n/a
management protocol related to the AS
II/0015
Submission of the final report from the non-clinical 
10/12/2020
n/a
study BMN-165-18-080 listed as a category 3 study 
in the RMP.
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission 
of studies to the competent authority
IB/0013/G
This was an application for a group of variations.
30/09/2020
n/a
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process
B.II.g.5.c - Implementation of changes foreseen in 
an approved change management protocol - For a 
biological/immunological medicinal product
IB/0011/G
This was an application for a group of variations.
14/09/2020
n/a
A.7 - Administrative change - Deletion of 
manufacturing sites
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
Page 5/9
changes to an approved test procedure
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate
II/0007/G
This was an application for a group of variations.
03/09/2020
26/03/2021
SmPC
During long-term pegvaliase treatment, sustained clinically 
Update of sections 4.4, 4.8 and 5.1 of the SmPC 
based on final results from studies 1655-003, a long-
term extension of a Phase 2, open-label, dose-
finding study and 165-302 a Phase 3, randomised, 
double-blind, placebo-controlled, four-arm, 
discontinuation study which are listed in the RMP as 
category 3 studies. The RMP version 2.0 has also 
been submitted.
meaningful blood phenylalanine lowering effect was 
observed; and most adverse events rates decreased.
Page 6/9
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data
PSUSA/10761
Periodic Safety Update EU Single assessment - 
11/06/2020
n/a
PRAC Recommendation - maintenance
/201911
pegvaliase
IB/0010
B.I.a.4.z - Change to in-process tests or limits 
02/06/2020
n/a
applied during the manufacture of the AS - Other 
variation
IB/0009/G
This was an application for a group of variations.
04/05/2020
n/a
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter)
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS
Page 7/9
II/0002
B.II.g.2 - Introduction of a post approval change 
16/01/2020
n/a
management protocol related to the finished product
PSUSA/10761
Periodic Safety Update EU Single assessment - 
16/01/2020
n/a
PRAC Recommendation - maintenance
/201905
pegvaliase
IG/1141
B.II.b.2.c.1 - Change to importer, batch release 
12/12/2019
n/a
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing
IAIN/0006/G
This was an application for a group of variations.
11/12/2019
n/a
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site
IB/0004
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
07/11/2019
n/a
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data
IB/0003
B.II.b.2.a - Change to importer, batch release 
08/10/2019
n/a
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
Page 8/9
control/testing takes place
Page 9/9
